The market players in the Immunotherapy
Drugs Market are actively seeking collaborations and partnerships for the
development of novel immunotherapy drugs. For instance, in April 2018,
Bristol-Myers Squibb Company (BMS) and Illumina Inc. collaborated to utilize
Illumina’s next-generation sequencing (NGS) technology to develop and globally
commercialize in-vitro diagnostic (IVD) assays in support of BMS oncology
portfolio. The collaboration helped to develop a diagnostic version of Illumina’s
TruSight Oncology 500 assay, including tumor mutation burden (TMB), and
microsatellite instability for immunotherapies.
Immunotherapy is the management
of a disease by enhancing, suppressing, or inducing an immune response. Some
immunotherapies are designed to magnify or elicit an immune response. They are
known as activation immunotherapies. However, some immunotherapies that
suppress or reduce the immune response are known as suppression
immunotherapies. Cell-based immunotherapies are useful for some types of
cancers. Immune effector cells including macrophages, dendritic cells,
lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells (NK Cell),
etc., work collectively to protect the body against cancer by aiming at
abnormal antigens articulated on the facade of the tumor cells. Therapies
including granulocyte colony-stimulating factor (G-CSF), imiquimod, interferons
as well as parts of cellular membrane from bacteria are approved for medical
use. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosine
phosphate-guanosine (CpG) oligodeoxynucleotides and glucans anda variety of
chemokines are involved in preclinical and clinical studies.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/525
An increase in the prevalence of
cancer and a number of autoimmune diseases, the demand for immunotherapy drugs
is likely to increase. The impact of these diseases can be ascertained from the
fact that cancer caused 9.6 million deaths in 2018, as reported by the World
Health Organization (WHO). The organization further stated that around 70% of
deaths from cancer occur in low and middle-income countries. Moreover, with the
rising need for mAbs, the immunotherapy drugs market is anticipated to have a
positive outlook till the end of the forecast period 2019-2027. MAbs have a
high affinity towards the specific disease cells as well as areas that require
treatment. Accordingly, they can be utilized for therapies such as
antibody-directed enzyme prodrug therapy and radio immunotherapy. The increased
use of these antibodies in the drug development process is likely to boost the
market’s revenue making capacity over the forecast period.
Another important factor driving
the growth prospects of the global immunotherapy drugs market is the
materialization of biosimilars. Dissimilar to generic drugs that have active
pharmaceutical ingredients like original drugs, biosimilars are nearly
identical to their creator biologic compounds. In view of the fact that
biosimilars are less expensive than biologics therefore the sale of biosimilars
among the patients and hospitals is likely to rise considerably during the
forecast period. This is expected to augment the overall growth of the
immunotherapy drugs market.
On the basis of therapy area, the
cancer segment is likely to hold the maximum market share in 2018. The large
share along with the high growth of this segment is due to the high
predilection for immunotherapy as a first line of treatment in the management
of cancer thereby leading to rising demand for the global immunotherapy drugs.
On the basis of product type, the mAbs segment accounted for the maximum share
of the market. The improvement of new drugs as well as the entry of new
molecules such as zanolimumab, elotuzumab, onartuzumab, and obinutuzumab into
the market will drive the growth of the global immunotherapy drugs market over
the forecast period.
Increasing prevalence of cancer
and rise in demand from the Asia Pacific region will drive the overall
immunotherapy drugs market
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/immunotherapy-drugs-market-525
According to National Cancer
Institute, around 1,685,210 new cases of cancer are likely to be diagnosed in
the U.S. in 2016 and about 595,690 people are estimated to die from the
disease. Since immunotherapy is used as a first line of treatment in the
management of cancer, the market immunotherapy drugs market will grow accordingly.
North America is the largest region in the global immunotherapy drugs market
and is expected to retain its dominance over the forecast period. Asia Pacific
is likely to be the fastest-growing market over the forecast period. The
elevated growth of this region can mainly be attributed to low cost of
manufacturing of these drugs in the region, rising pricing and reimbursement
scenario for immunotherapy drugs on the universal level and for major countries
such as the Belgium, the U.K., France, Italy, Spain, Japan, China, and
Australia. For instance, reimbursement scenario in the U.K. has impacted the
cost of the drugs. Keytruda is an immunotherapy drug used for the treatment of
melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer
(HNSCC), urothelial carcinoma, gastric cancer, and cervical cancer. Keytruda
generally costs up to US$ 84,000 to the patients. To reduce the cost of this
drug, the National Health Service (NHS) England, a publicly funded national
healthcare system, and Merck & Co. Inc. entered into an agreement in June
2018, to reimburse the cost of this drug and provide it for routine use as per
the National Institute for Health and Care Excellence (NICE) recommendations.
NICE recommends NHS to provide reimbursements for this drug and make it
affordable for the patients.
Similarly, in April 2018, Pfizer
Inc. and Allogene Therapeutics Inc. entered into an asset contribution
agreement to use Pfizer’s portfolio related to allogeneic CAR-T therapy, an
investigational immune cell therapy, for cancer. This agreement acted as an
attractive opportunity for Pfizer Inc. to continue the development of CAR-T
therapy.
Some of the companies operating
in the immunotherapy drugs market in the current scenario are GlaxoSmithKline,
F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc.,
Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca
plc and Johnson & Johnson.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/525
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment